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Abstract 
The hydrolysis of sulfate ester conjugates is frequently required prior to analysis for a range of analytical 
techniques including gas chromatography-mass spectrometry (GC-MS). Sulfate hydrolysis may be achieved 
with commercial crude arylsulfatase enzyme preparations such as that derived from Helix pomatia but 
these contain additional enzyme activities such as glucuronidase, oxidase and reductase that make them 
unsuitable for many analytical applications. Strong acid can also be used to hydrolyse sulfate esters but this 
can lead to analyte degradation or increased matrix interference. In this work, the heterologously 
expressed and purified arylsulfatase from Pseudomonas aeruginosa is shown to promote the mild enzyme-
catalysed hydrolysis of a range of steroid sulfates. The substrate scope of this P. aeruginosa arylsulfatase 
hydrolysis is compared with commercial crude enzyme preparations such as that derived from H. pomatia. 
A detailed kinetic comparison is reported for selected examples. Hydrolysis in a urine matrix is 
demonstrated for dehydroepiandrosterone 3-sulfate and epiandrosterone 3-sulfate. The purified P. 
aeruginosa arylsulfatase contains only sulfatase activity allowing for the selective hydrolysis of sulfate 
esters in the presence of glucuronide conjugates as demonstrated in the short three-step chemoenzymatic 
synthesis of 5-androstane-3,17-diol 17-glucuronide (ADG, 1) from epiandrosterone 3-sulfate. The P. 
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aeruginosa arylsulfatase is readily expressed and purified (0.9 g per L of culture) and thus provides a new 
and selective method for the hydrolysis of steroid sulfate esters in analytical sample preparation. 
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Introduction 
Steroid metabolites from both exogenous and endogenous sources are typically excreted in biological fluids 
as phase II glucuronide or sulfate conjugates.[1][2] They are of growing importance in fields such as sports 
drug testing,[3] the detection of residues in agricultural produce,[4] and medicine.[5] In the context of sports 
drug testing, hydrolysis of these conjugates may be required prior to routine screening, confirmatory 
analysis, or more advanced techniques such as gas chromatography-isotope ratio mass spectrometry (GC-
IRMS). The hydrolysis of phase II glucuronide conjugates can generally be achieved under mild conditions 
using the Escherichia coli -glucuronidase enzyme (3.2.1.31).[3][6] This approach has remained a mainstay of 
anti-doping laboratories where enzyme hydrolysis is followed by derivatisation and gas chromatography-
mass spectrometry (GC-MS) analysis to screen the combined free and glucuronide conjugated steroidal 
fractions.[7]  
In contrast, no generally accepted method has been established for the hydrolysis of phase II steroidal 
sulfate conjugates, and they are not routinely included in human anti-doping screens.[3][8][9] Steroid sulfates 
represent a significant fraction of the steroid metabolites and including them in analysis could improve the 
sensitivity and retrospectivity of sports drug testing. For example, the analysis of sulfate metabolites can 
afford greater retrospectivity for the detection of steroidal agents,[10][11][12] and may also serve as markers to 
distinguish between steroids of exogenous and endogenous origin.[12][13][14] Other non-steroidal 
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performance-enhancing drugs also afford important sulfate conjugates, including toremifene,[15] 
andarine,[16] and mesocarb.[17][18]  
Steroid sulfates can be chemically hydrolysed under strong acid conditions, but this can degrade acid-
sensitive analytes and may also give rise to increased matrix-derived interference in the subsequent GC-MS 
analysis leading to reduced sensitivity.[3][19] A range of commercial sulfatase enzymes (EC 3.1.6.1) may be 
employed, but these crude enzyme preparations typically have additional activities such as -
glucuronidase, oxidase or reductase that make them unsuitable for many applications.[3][19] To address 
these issues a number of more elaborate protocols have been employed including, glucuronide hydrolysis 
and extraction of free steroids prior to sulfate hydrolysis, or separation of the sulfate fraction through solid 
phase extraction prior to strong acid or enzyme hydrolysis. The approaches and challenges associated with 
analysis of the sulfate fraction have been reviewed in detail.[3]  
In this work we report a study of the steroid sulfatase activity of the heterologously expressed and purified 
Pseudomonas aeruginosa arylsulfatase (PaS) including substrate scope and enzyme kinetic evaluation. 
These results are compared against four commercial sulfatase enzyme preparations. The PaS enzyme is 
shown to hydrolyse a range of steroid sulfates, with a substrate scope similar to that observed for Helix 
pomatia arylsulfatase preparation (HpS), the leading commercial crude enzyme preparation for the 
hydrolysis of steroid sulfates. Hydrolysis in a urine matrix is demonstrated for dehydroepiandrosterone 3-
sulfate and epiandrosterone 3-sulfate. In contrast to HpS, which displays significant -glucuronidase 
activity, PaS is a purified enzyme that allows for the selective hydrolysis of sulfate esters in the presence of 
glucuronide conjugates. This is illustrated by a short chemoenzymatic synthesis of 5α-androstane-3β,17β-
diol 17-glucuronide (ADG) 1.  
 
Experimental 
Materials 
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Unless otherwise stated, chemicals were purchased from Sigma–Aldrich (Castle Hill, Australia). 
Androsterone (A), boldenone (B), epiandrosterone (EA), etiocholanolone (EC), nandrolone (N) and 
testosterone (T) were obtained from Steraloids (Rhode Island, USA). Dehydroepiandrosterone (DHEA) was 
obtained from BDH (Poole, UK). Epiandrosterone-d5 (2,2,3,4,4-d5; EA-d5) manufactured by CDN Isotopes 
Inc. (Pointe-Claire, Canada) was purchased from SciVac Pty. Ltd. (Hornsby, Australia). Epitestosterone (ET) 
was synthesised from T using literature methods.[20] Milli-Q water was used in all aqueous solutions and in 
the liquid chromatography mobile phase. Liquid chromatography (gradient) grade methanol obtained from 
Merck (Kilsyth, Australia) was used for preparing the LC mobile phase and steroid standard solutions.  
Synthesis of steroid sulfates 
To explore the substrate range of the sulfatases investigated, steroid sulfates were synthesised by 
literature methods.[21][22][23] All steroid sulfates were prepared in high purity following recrystallization with 
characterization by m.p., [α]D, 
1H and 13C NMR, LRMS and HRMS. An ‘S’ at the end of a steroid abbreviation 
denotes sulfation of a hydroxyl group. 
Commercial enzymes 
Four arylsulfatase preparations (EC 3.1.6.1) were purchased from Sigma–Aldrich for comparison with PaS. 
Three were derived from molluscs: H. pomatia sulfatase (HpS) (product number S9626), Haliotis rufescens 
(abalone) sulfatase (HrS) (S9754), and Patella vulgata sulfatase (PvS) (S8629). Stock solutions of each were 
prepared by dissolving 10 mg of solids per ml of 250 mM ammonium acetate at pH 6.9. The fourth 
preparation was Aerobacter aerogenes sulfatase, purchased as a solution in aqueous glycerol (S1629). The 
bacterium from which this fourth sulfatase is derived is also known as Klebsiella pneumoniae[24] and since 
this name is used exclusively in current literature it is referred to here as K. pneumoniae sulfatase (KpS). 
The four commercial sulfatase preparations are reported to have -glucuronidase activity in the Sigma–
Aldrich product information. One other sulfatase, from Flavobacterium heparinum (Pedobacter heparinus), 
is commercially available. This is classified as a disulfoglucosamine-6-sulfatase (EC 3.1.6.11) and was not 
evaluated as part of this research.[25] 
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PaS preparation 
The protein sequence for PaS was obtained from Genbank (Accession No. AAG03573.1); derived from the P. 
aeruginosa genome sequence.[26] The sequence was submitted to DNA2.0 (California, USA) for codon 
optimization (for expression in E. coli), gene synthesis, inclusion of a C-terminal His-tag (six His residues) 
and insertion into expression vector pJExpress404. This plasmid confers ampicillin resistance and placed 
PaS expression under tight control of the T5 promoter and LacI repressor. This construct was transformed 
into electro-competent E. coli DH5α using a BioRad (Gladesville, Australia) electroporator according to 
manufacturer’s instructions. Transformants were selected on Lysogeny Broth supplemented with 100 mg L–
1 ampicillin (LBA) agar plates and a single colony was selected to inoculate 2 mL of LBA media. This culture 
was incubated at 37 °C overnight and used to inoculate 0.5 L of Terrific Broth with 50 mg L–1 ampicillin and 
0.1 mM isopropyl -D-1-thiogalactopyranoside in a 1 L conical flask. The flask was incubated at 25 °C with 
200 rpm shaking for 44 hours before chilling on ice. The culture was centrifuged at 8000 × g to pellet the 
bacteria and the supernatant was discarded. The cells were resuspended in 10 mL of cold buffer A (50 mM 
Tris-sulfate at pH 7.5, 0.3 M NaCl, and 0.1 mM CaCl2) per 1 g of wet cell pellet. The suspension was lysed 
using a French pressure cell at 12000 psi. Ammonium sulfate (0.2 g mL–1) was dissolved in the lysate and 
then left on ice for 20 min to precipitate unwanted protein. The mixture was centrifuged at 30000 × g for 
30 min and the supernatant was collected. Another 0.2 g mL–1 of ammonium sulfate was dissolved in the 
supernatant to precipitate most of the PaS activity. The sample was centrifuged again at 30000  g for 30 
min and the pellet was dissolved in buffer A containing 30 mM imidazole. This sample was loaded onto a GE 
Healthcare (Silverwater, Australia) 5 mL HisTrap™ column with chelated Ni2+ and washed with 30 mL of 
buffer A containing 30 mM imidazole. PaS was then eluted from the column in buffer A containing 200 mM 
imidazole and fractions with para-nitrophenyl sulfate (PNPS) hydrolysis activity were pooled. For enzyme 
characterisation studies, the pooled fractions were extensively dialysed against 50 mM Tris-sulfate at pH 
7.5, filter-sterilised (0.2 µm membrane) and stored in aliquots at approximately 1 g L–1 and –20 °C. Frozen 
aliquots were thawed immediately before use and then stored at 4 °C. The sulfatase activity remained 
stable during storage: for several months at 4 °C, or for more than a year at −20 °C.  
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Concentrated PaS for application in anti-doping labs was prepared as follows. The pooled fractions with 
PNPS hydrolysis activity had 0.5 g L–1 ammonium sulfate added to precipitate most of the PaS at 4 °C for at 
least one hour. The mixture was centrifuged at 15000 × g for 15 min and the white pellet was then washed 
with 50 mL of 50 mM Tris-sulfate buffer at pH 7.4 with 0.5 g L–1 ammonium sulfate. Centrifugation was 
repeated as before and the pellet was dissolved in 60% (v/v) glycerol, 50 mM Tris-sulfate at pH 7.4 (4 °C) for 
a final volume equivalent to 1% of the original culture volume for approximately 70 g L–1. Concentration 
was determined by Bradford assay with bovine serum albumin as a standard. Samples were more than 95% 
pure based on SDS-PAGE stained by Colloidal Coomassie Blue G25 (BioRad, Gladesville, Australia) and 
reproduced in the Supporting Information (supplementary figure 1). 
Analyte quantification 
Spectrophotometry for para-nitrophenol (PNP). The hydrolysis of PNPS was monitored by measuring the 
absorption of 405 nm light by the PNP anion. Assays were performed in 96-well plate format with filled 
wells to obtain a 10 mm path length. Reactions or standards (300 L) were mixed with 50 µL of 1 N KOH to 
ensure complete ionisation of PNP and to quench enzyme activity. The extinction coefficient for PNP with 
this method was 14,147 M–1 cm–1 determined with PNP standards from 0.3 to 40 µM (r2 > 0.9995). 
Liquid chromatography-mass spectrometry (LC-MS) for steroids and their derivatives. Steroids and steroid 
conjugates were separated using an Agilent (Mulgrave, Australia) 1260 UHPLC system with a Grace 
(Rowville, Australia) C18 column (50 mm with 5 mm guard column, 2 mm diameter, 1.8 m particle size). 
The mobile phase consisted of 58% methanol and 42% aqueous ammonium acetate for analysis of steroid 
sulfates or 62% methanol and 38% aqueous ammonium acetate for steroid glucuronides. Both mobile 
phases had a final concentration of 10 mM ammonium acetate. Analytes were ionised by atmospheric 
pressure electrospray ionisation (AP-ESI) with an Agilent 6120 quadrupole mass spectrometer: estrone (E), 
the steroid sulfates and the steroid glucuronide were monitored in negative mode for the proton-loss 
species ([M–H]–), the steroid 3-sulfate, 17-glucuronide for the dianion ([M–2H]2–), and the remaining free 
steroids in positive mode for the proton adducts ([M+H]+). Negative and positive ions were monitored 
simultaneously with switching time optimised for analyte peak widths of 0.15 min. Capillary voltage and 
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fragmentation voltage were optimised for each analyte and are specified in the Supporting Information 
(supplementary table 1). 
Enzyme assays. The mollusc enzyme preparations HpS, HrS, or PvS were assayed in 50 mM ammonium 
acetate at pH 5.0 (pH was selected according to the activity defined by Sigma–Aldrich and the buffer was 
selected for compatibility with LC-MS), KpS was assayed in 50 mM Tris-HCl at pH 7.4,[27] and PaS in 50 mM 
Tris-acetate at pH 8.8.[28] Each enzyme preparation was assayed for protein concentration using the 
Bradford assay with bovine serum albumin as a standard. The final enzyme concentrations used in the 
various assays are listed in the Supporting Information (supplementary table 2). Reaction components to be 
analysed by LC-MS were centrifuged at 16000 × g for 3 min before transferring to clean vials for pre-
incubation in a temperature controlled autosampler. All reactions were performed at 37 °C. Aliquots of 
enzyme and substrate were prepared and pre-incubated at 37 °C for 3 min before mixing enzyme with 
substrate to start reactions. Samples of the reaction were quenched by either addition of aqueous 
potassium hydroxide solution (1 M) for PNP detection or injection into LC mobile phase for analysis of 
steroid sulfate hydrolysis.  
Substrate scope studies (Table 1) used 100 µM steroid sulfate. For kinetic analysis (Table 2; Supporting 
Information, supplementary figure 2), the substrate concentration range was prepared by serial two-fold 
dilution to cover 2.5 to 320 M in reactions. Each enzyme-substrate combination was tested in three 
independent technical replicates (i.e. prepared and analysed at different times, but with the same samples 
of enzyme and substrate). Non-linear regression was used to fit concentration rate data to the Michaelis–
Menten model or to a model with substrate inhibition included[29] to estimate kinetic parameters. 
Evaluation of PaS activity in a urine matrix 
The collection of urine samples was conducted with approval of the Australian National University Human 
Research Ethics Committee. 
Hydrolysis of steroid sulfates by PaS in a urine matrix. Aliquots of human urine (3 mL) were pipetted into 
test tubes (8 mL) and epiandrosterone-d5 (EA-d5, 5 g mL
–1) was added as internal standard. The samples 
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were adjusted to pH 9.0 ± 0.2 with the addition of aqueous ammonia solution (10% v/v) and mixing before 
the addition of PaS enzyme (50 L, final concentration of 1 g L–1) and overnight incubation at 37 °C. Free 
steroids were isolated by solid phase extraction using an Agilent ABS Elut NEXUS® extraction cartridge (60 
mg, 3 cc,) that was conditioned with methanol (3 mL) and water (3 mL), then loaded with the hydrolysis 
reaction and washed with aqueous sodium hydroxide solution (1 mL, 0.1 M) and water (3 mL), before 
elution with methanol (3 mL). The eluant was evaporated to dryness under nitrogen at 60 °C before the 
liberated steroids were derivatised to form trimethylsilyl (TMS) ethers and TMS enol ethers using N-methyl-
N-(trimethylsilyl)trifluoroacetamide/ammonium iodide/dithiothreitol (50 L, 1000:2:4 w/v/v) at 80 °C for 
60 min. The final extracts were dried under nitrogen at 60 °C before being reconstituted in n-dodecane (50 
L) for GC-MS-MS analysis. 
Detection of free steroids by GC-MS-MS of TMS derivatives. An Agilent 7000B GC-MS-MS was employed. 
The GC column was an Agilent J&W HP5-MS (30 m  0.25 mm  0.25 m) with helium as carrier gas. 
Sample injections (1 L) were made in pulsed-splitless mode with an injector temperature of 250 °C. The 
column temperature was initially held at 182 °C for 1 min, then was increased at 2 °C min–1 to 220 °C and 
held for 5 min, then increased to 310 °C at 30 °C min–1 and held for 1 min. Head pressure was programmed 
to maintain a constant flow rate of 1.2 mL min–1. The MS transfer line was set at 300 °C and the ion source 
was operated in positive electron ionisation (+EI) mode with an ionization energy of 70 eV. Nitrogen was 
used for the collision gas at 1.5 mL min–1. Instrument control and processing was performed using Agilent 
MassHunter® software. Multiple reaction monitoring (MRM) was used to identify derivatised DHEA and EA 
as specified in the Supporting Information (supplementary table 3), with limit of detection for both analytes 
at 0.1 ng mL–1. Specificity for both steroids was evaluated following injection of neat standards to ensure 
there was no ‘crosstalk’ between the MRM transitions. 
Synthesis of 5-androstane-3,17-diol 17-glucuronide (ADG) 1[30] 
5-androstane-3,17-diol 3-sulfate (ADS) triethylammonium salt 2. Epiandrosterone 3-sulfate 
triethylammonium salt[21][22] 3 (198 mg, 0.42 mmol) in distilled methanol (2 mL) was added drop-wise to 
solid sodium borohydride (86 mg, 2.27 mmol, 5.4 equiv.) at 0 °C. After the vigorous reaction had subsided, 
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the reaction was allowed to warm to room temperature and stirred until complete by TLC. The reaction 
was quenched with saturated aqueous sodium bicarbonate solution (25 mL) and extracted with ethyl 
acetate (6  20 mL) and then 3:1 chloroform-isopropanol solution (6  20 mL). The combined organic layers 
were dried with magnesium sulfate and concentrated under reduced pressure to yield pure 5-androstane-
3,17-diol 3-sulfate triethylammonium salt 2 (157 mg, 79%) as an off-white solid. Copies of the 1H and 13C 
NMR spectra (supplementary figures 3–5) are provided in the Supporting Information. Rf 0.31 (7:2:1 EtOAc : 
MeOH : H2O); m.p. 215–220 °C; []D
25 +32 (c 10, MeOH); 1H NMR (400 MHz, CD3OD)  4.35 (1H, m, H3), 
3.60 (1H, t, J 8.6, H17), 3.00 (6H, m, N(CH2CH3)3), 2.50–0.85 (22H, m), 1.30 (9H, t, J 7.4, N(CH2CH3)3), 0.85 
(3H, s, H18), 0.80 (3H, s, H19); 13C NMR (100 MHz, CD3OD)  82.5, 79.7, 55.9, 52.3, 47.8, 46.3, 44.1, 38.2, 
38.0, 36.9, 36.5, 36.3, 32.8, 30.6, 29.7, 24.3, 21.9, 12.7, 11.7, 9.4, one carbon overlapping or obscured; 
LRMS (–ESI) m/z 371 ([M–Et3NH]
–, 100%), 97 ([HSO4]
–, 30%); HRMS (–ESI) m/z found 371.1892, C19H31O5S 
([M–Et3NH]
–) requires 371.1892.  
5-androstane-3,17-diol 3-sulfate, 17-glucuronide (ADSG) 4. 5-androstane-3,17-diol 3-sulfate 
triethylammonium salt 2 (1.00 mg, 2.11 mol) was dissolved in tert-butanol (320 L) and sodium phosphate 
buffer (2.05 mL, 50 mM, pH 7.5). Glucuronylsynthase enzyme solution (0.58 mL, 1.09 g L–1, final 
concentration 0.2 mg mL–1)[31] and -D-glucuronyl fluoride 5 (2.3 mg, 10.8 mol, 5 equiv.)[31] dissolved in 
sodium phosphate buffer (220 L, 50 mM, pH 7.5) were added and the reaction incubated without 
agitation at 37 °C for 2 d. The reaction was then subjected to solid-phase extraction to remove non-volatile 
salts and other reaction components.[32] A Waters (Rydalmere, Australia) Oasis WAX SPE cartridge (60 mg, 3 
cc) was conditioned with methanol (1 mL) and milliQ water (3 mL). The crude reaction mixture was loaded 
onto the cartridge and washed with aqueous formic acid (3 mL, 2% v/v), milliQ water (3 mL), and finally 
with ammonium hydroxide in methanol (9 mL, 5% v/v). The appropriate fractions were combined and the 
solvent removed under reduced pressure at 40 °C to afford a mixture of 5-androstane-3,17-diol 3-
sulfate, 17-glucuronide (ADSG) 4 and 5-androstane-3,17-diol 3-sulfate (ADS) 2 with a 31% conversion as 
determined by 600 MHz 1H NMR integration of the H17 protons. A copy of the 1H NMR conversion 
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spectrum (supplementary figure 6) is provided in the Supporting Information. The crude mixture was used 
directly in the subsequent enzyme hydrolysis step.  
5-androstane-3,17-diol 17-glucuronide (ADG) 1.[30] The selective hydrolysis of 5-androstane-3,17-
diol 3-sulfate, 17-glucuronide (ADSG) 4 (1 mM) prepared above was performed at 37 °C with PaS enzyme 
preparation (final concentration of 0.8 g L–1 in Tris-acetate buffer (50 mM, pH 9) with a final volume of 1 
mL. After four to six hours incubation, 1 mL of 0.8 g L−1 PaS in Tris-acetate buffer (50 mM, pH 9) was added. 
This step replenished enzyme activity and allowed complete hydrolysis after an additional four hours at 37 
°C. The reaction was then quenched with methanol, 50% (v/v) final concentration, and then subjected to 
solid-phase extraction to remove non-volatile salts and other reaction components. A Waters Oasis WAX 
SPE cartridge (60 mg, 3 cc) was conditioned with methanol (1 mL) and milliQ water (3 mL). The crude 
reaction mixture was loaded onto the cartridge and washed with aqueous formic acid (3 mL, 2% v/v), milliQ 
water (3 mL), methanol (3 mL), and finally with ammonium hydroxide in methanol (9 mL, 5% v/v) to elute 
the steroid glucuronide. The appropriate fractions were combined and the solvent removed under reduced 
pressure at 40 °C to afford ADG 1 as a white solid. A copy of the 600 MHz 1H NMR spectrum 
(supplementary figure 7) and low-resolution mass spectrum (supplementary figure 8) are provided in the 
Supporting Information. Rf 0.30 (7:2:1 EtOAc : MeOH : H2O); 
1H NMR (400 MHz, CD3OD)  4.35 (1H, d, JH20–
H21 7.8, H20), 3.81 (1H, t, JH17–H16 8.7, H17); 3.52–3.19 (5H, m), 2.07 (1H, m), 1.96 (1H, m), 1.77–1.50 (6H, m), 
1.45–1.10 (11H, m), 1.03–0.90 (2H, m), 0.84 (3H, s, CH3), 0.83 (3H, s, CH3), 0.66 (1H, m); LRMS (–ESI) m/z 
467 ([M–H]–); HRMS (–ESI) m/z found 467.2641, C25H39O8 ([M–H]
–) requires 467.2645.  
 
Results 
Sulfatase substrate range 
Our initial research objective was to evaluate the four commercially derived sulfatase preparations 
alongside the heterologously expressed and purified PaS to establish substrate ranges for PNPS and steroid 
sulfate hydrolysis (Scheme 1). Activity, relative to total protein concentration, was measured by LC-MS or 
11 
spectrophotometry at a single 100 M substrate concentration. Ten substrates, selected to encompass the 
structural diversity of commonly occurring steroid sulfates, were tested with each of the five enzymes and 
the resulting activity scored on a logarithmic scale (Table 1).  
The commercial enzyme HpS was observed to hydrolyse the greatest number of sulfate substrates with 
only two steroid sulfates proving recalcitrant: androsterone 3-sulfate (AS) and epitestosterone 17-sulfate 
(ETS). The small aromatic substrate, PNPS, at 100 M was hydrolysed most readily by HpS with a rate of 
1.07 mmol min–1 (g protein)–1. In decreasing order of hydrolysis rates with 100 M substrate concentration 
were: estrone 3-sulfate (ES, nine-fold slower than PNPS), dehydroepiandrosterone 3-sulfate (DHEAS), 
epiandrosterone 3-sulfate (EAS), boldenone 17-sulfate (BS), etiocholanolone 3-sulfate (ECS), testosterone 
17-sulfate (TS), and nandrolone 17-sulfate (NS, 95,000-fold slower than PNPS).  
The heterologously expressed and purified PaS showed a similar activity profile to HpS, except ECS was not 
significantly hydrolysed. Like HpS, the range of activity covered five orders of magnitude, from PNPS (13.4 
mmol min–1 [g protein]–1) and ES (1.6-fold slower than PNPS) to BS (175,000-fold slower than PNPS). PaS 
was similar to HpS for hydrolysis of EAS per gram of protein. In comparing these enzymes with 100 M 
substrate, PaS was faster with PNPS (13-fold), ES (69-fold), NS (46-fold), or TS (4-fold). In contrast, PaS was 
slower than HpS with DHEAS (3-fold) or BS (2-fold).  
The other commercial sulfatases studied had narrower substrate ranges and lower activity per gram of 
protein. For example, HrS was capable of hydrolysing six of the ten substrates, showing an attenuated 
activity and substrate range relative to HpS and PaS. This enzyme preparation was unable to hydrolyse BS 
or NS and showed low activity with TS. Similarly, PvS could only hydrolyse four of the substrates but 
showed the least discrimination between phenolic and secondary hydroxyl-derived steroid sulfates, with 
similar rates observed for ES and EAS. Interestingly, DHEAS was hydrolysed ten-fold slower than EAS; these 
two similar substrates showed more consistent rates of hydrolysis with the other enzyme preparations. 
Finally, KpS exhibited the lowest sulfatase activity, with 240000-fold less activity per gram of protein than 
PaS for the model substrate PNPS. Furthermore, KpS showed no detectable hydrolysis activity for any of the 
steroid sulfates tested. 
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The two most active and promiscuous sulfatases PaS and HpS were selected for further analysis. The 
commercial sulfatase preparation HpS gave the broadest substrate range, hydrolysing eight of the ten 
substrates. The heterologously expressed and purified PaS was free of glucuronidase activity and had 
strong arylsulfatase activity on seven of the substrates tested (Table 1). 
Kinetic analysis of P. aeruginosa and H. pomatia sulfatases 
Substrate-saturation kinetics was measured in triplicate for PaS and HpS with four representative 
substrates: PNPS, ES, EAS and TS. Replicates gave consistent results. However, the replicates had greater 
variation with the poorest substrate, TS, and when substrate inhibition was observed (Supporting 
Information, supplementary figure 2). Michaelis–Menten substrate saturation kinetics explained the results 
for all except the hydrolysis of ES by PaS. This combination displayed substrate inhibition and an additional 
parameter (KI) was included in the model giving an improved fit to the data.
[29] The Michaelis constant (KM) 
was in the range of 7 to 90 M for all substrate-enzyme combinations (Table 2) with PaS showing 
significantly lower KM than HpS for PNPS, ES, and EAS, but no significant difference with TS (based on 95% 
confidence intervals).  
An inspection of Vmax values (Table 2) showed that PaS was faster per gram of protein than HpS for PNPS, 
ES, or TS, but not EAS. The greatest difference in Vmax was seen with ES which was hydrolysed 65-fold faster 
by PaS. In contrast, EAS was hydrolysed by HpS two-fold faster than by PaS. Both PaS and HpS showed 
greater maximum hydrolysis rates for the aromatic sulfate esters PNPS and ES, although PaS had a greater 
bias in favour of the aromatic substrates than HpS. This can be seen when Vmax is normalised for the model 
substrate, PNPS: PaS hydrolyses ES three-fold faster than HpS whereas HpS hydrolyses EAS 50-fold faster, 
or TS five-fold faster. 
Hydrolysis of steroid sulfates in urine 
DHEAS. Due to the endogenous contribution of urinary DHEA and DHEAS, buffer spikes were required to 
assess the hydrolysis efficiency of PaS (61 ± 4%, n = 3) from spiked DHEAS (100 ng mL–1 DHEA equiv.). 
Method recovery without urine matrix contribution was assessed from pre- and post-extraction DHEA 
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spikes at 100 ng/mL to be 95%. In urine, hydrolysis with PaS demonstrated a more than 200-fold increase in 
DHEA when compared to control experiments not containing PaS (Supporting Information, supplementary 
figure 9). Selectivity was achieved for DHEA in urine with no matrix interferences observed for any of the 3 
MRM transitions monitored. Compared with HpS and acid hydrolysis methods,[33] PaS afforded 25% and 
150% increased yields of DHEA in urine respectively. Matrix background observed from all three hydrolysis 
types was compared using peak areas normalised to DHEA that showed PaS to be equivalent to HpS. These 
were not as clean as the extract from acid hydrolysis, which was estimated to have one-quarter of the 
background based on the percentage of total peak areas. However, this result was not surprising, 
considering the acid hydrolysis procedure included an additional liquid-liquid extraction step.  
EAS. The hydrolysis efficiency of PaS for EAS was estimated at 42 ± 3% (n = 3) from buffer spikes at 100 ng 
mL–1 (EA equiv.). Method recovery without urine matrix was estimated at 92%. Poor selectivity for EA in 
urine was observed with the 434>169 and 434>239 transitions exhibiting co-eluting matrix interferences 
that allowed only partial resolution of the EA peak. Additional sample purification was attempted with C18 
(Waters, Milford, MA, USA) solid phase extraction of urine samples prior to hydrolysis, but no improvement 
was found. The 434>239 transition was therefore used to monitor the efficacy of PaS. Hydrolysis with PaS 
increased EA from undetectable levels to a signal intensity of 2  104 in urine (Supporting Information, 
supplementary figure 10). Analysis of urinary EA was superior using PaS when compared to HpS, with the 
latter suffering from reduced sensitivity and selectivity. In comparison to the acid hydrolysis,[33] the PaS 
extract provided similar signal intensity, though the matrix background determined from normalised peak 
areas was approximately half. 
Chemoenzymatic synthesis of 5-androstane-3,17-diol 17-glucuronide (ADG) 1 
The commercially available sulfatase preparations are all reported to contain -glucuronidase activity. In 
contrast, PaS is a purified enzyme, raising the prospect of selective sulfate ester hydrolysis in the presence 
of glucuronide conjugates. The E. coli strain used in PaS expression, DH5α, is capable of -glucuronidase 
expression, so the PaS preparation was tested for this activity by incubating 1 g L–1 PaS with 5 mM 
p-nitrophenyl--D-glucuronide in 50 mM Tris-acetate at pH 8.8 at 37 °C. No hydrolysis to liberate the yellow 
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PNP anion was observed after overnight incubation, indicating that PaS was a suitable catalyst for the 
selective hydrolysis of sulfate ester conjugates. 
To demonstrate this capacity for selective hydrolysis, a short chemoenzymatic synthesis of ADG 1 from EAS 
3 was conducted (Scheme 2). Sodium borohydride-mediated reduction of EAS afforded 5-androstane-
3,17-diol 3-sulfate (ADS) triethylammonium salt 2. This was then subjected to glucuronylation of the 
17-hydroxy group employing a synthetically-derived 1--glucuronyl fluoride 5 donor in conjunction with 
the glucuronylsynthase catalyst derived from E. coli -glucuronidase.[31][32][34] This reaction afforded a 
mixture of ADS 2 and 5-androstane-3,17-diol 3-sulfate, 17-glucuronide (ADSG) 4 with a 31% conversion 
as determined by 600 MHz 1H NMR integration of the H17 protons. This mixture was used directly in the 
following hydrolysis experiments. 
On a small scale, hydrolysis of the mixture containing ADSG 4 (~20 M) with PaS was monitored by LC-MS 
which showed the consumption of both ADS 2 and ADSG 4 and the accumulation of ADG 1 (Figure 1). Under 
the ESI conditions of this LC-MS analysis the saturated 5-androstane-3,17-diol (AD) liberated from ADS 
2 was not observed. In contrast to the selective PaS hydrolysis, the use of HpS resulted in hydrolysis of both 
sulfate and glucuronide conjugates such that no ADG 1 was produced (data not shown). After 
demonstrating that the final step in Scheme 2 was possible with the purified PaS, the reaction was scaled 
up to ~1 mM ADSG 4 (Scheme 2). This produced a mixture of hydrolysis products with ADG 1 remaining as 
the sole conjugated steroid, which could be readily purified by SPE using an Oasis WAX mixed mode 
polymeric/weak anion exchange cartridge.[32] The data acquired for this compound was consistent with the 
proposed structure.[30]  
 
Discussion 
The objective of this research was to discover a sulfatase enzyme capable of the mild and selective 
hydrolysis of steroid sulfates for analytical applications. In this study, four of the five enzymes tested 
displayed some steroid sulfatase activity (Table 1). The commercially available crude enzyme preparation 
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HpS showed the greatest substrate range, with detectable hydrolysis of seven of the nine steroid sulfates 
investigated. The heterologously expressed and purified PaS also showed broad scope with reasonable 
activity for six of the nine steroid sulfates. The remaining commercially-derived sulfatase preparations HrS, 
PvS and KpS showed reduced substrate scope and lower activity against this range of steroid sulfates. Both 
PaS and HpS showed useful activity as steroid sulfatases, but none of the five sulfatases tested here 
provided comprehensive sulfatase activity against the nine steroid substrates tested. Although not 
investigated as part of this work, we anticipate that PaS will prove useful in the hydrolysis of sulfate 
metabolites, particularly aryl sulfates, of non-steroidal performance-enhancing drugs, including andarine,[16] 
and mesocarb.[17][18] 
Previous research by Cawley et al. on mollusc-derived sulfatase preparations uncovered marked 
preferences for certain steroid sulfates substitution patterns and configurations.[35] This work highlighted 
that HpS had a particularly broad substrate range when compared to other mollusc sulfatases such as PvS. 
The work also highlighted the dependence of HpS activity on the configuration of 3-hydroxyandrostan-17-
ones: relatively high activity for DHEAS (3,5-ene), EAS (3,5), and ECS (3,5); intermediate activity for 
3-hydroxy-5-androstan-17-one 3-sulfate (3,5); and no activity for AS (3,5). Our measurements of 
HpS activity correlate well with this activity profile and include additional data for several steroid 17-
sulfates: TS, BS, and NS (17) are hydrolysed whereas ETS (17) is not. Taken together, these results reveal 
significant differences in enzyme-substrate interactions and kinetic competence for the sulfatases studied. 
The bacterial sulfatase PaS appears to be slightly more constrained than the mollusc-derived HpS enzyme 
preparation given that it cannot hydrolyse ECS. However, in contrast to the recombinantly expressed PaS, it 
is not certain how many sulfatase isoforms are present in crude HpS preparation or how many contribute 
to the apparent steroid sulfatase activity. An attempt to isolate the genes responsible for HpS sulfatase 
activity indicated that at least three sulfatases are present, but only one was cloned as full-length 
complementary DNA. Attempted expression of this gene in either E. coli or Saccharomyces cerevisiae failed 
to afford functional enzyme,[36] which serves to highlight the limits of our understanding of these mollusc-
derived sulfatases.  
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There are subtle differences in activity and substrate range for PaS and HpS (Table 1). Greater activity per 
gram of protein is observed for PaS relative to HpS for TS and the 19-nor steroid, NS at 100 M substrate 
concentration. As noted above, HpS has activity for ECS, whereas PaS does not. The detailed kinetic analysis 
(Table 2) shows that PaS has lower KM for most substrates, though there was no significant difference for 
TS. Given that sports drug testing analysis or medical research typically involves low concentrations of 
steroid compounds (pM–M), a lower KM would be advantageous.  
For both enzymes, the substrate range from PNPS to TS show a difference in Vmax of five orders of 
magnitude (Table 2). The aryl sulfate esters can be hydrolysed more readily due to the conjugation afforded 
by the aromatic ring that provides increased stability for the leaving group.[37][38] The uncatalysed hydrolysis 
of the S–O bond in near-neutral water for PNPS has been determined as 1.9  10–10 s–1, and estimated by 
extrapolation for the n-pentyl sulfate as 3  10–26 s–1.[37] Therefore, even though the maximum rates of 
hydrolysis for the secondary alkyl sulfate TS is about four to five orders of magnitude slower than the aryl 
sulfates PNPS and ES, the rate enhancement afforded by HpS or PaS for TS may be significantly  greater 
(~1011-fold). It is worth noting that with reasonable catalytic rates for hydrolysis of an extremely stable S–O 
bond in alkyl sulfates, some alkyl sulfatases provide the greatest rate enhancements of the known 
enzymes.[37] 
Differences in maximum velocity were also observed with PaS displaying 25-fold greater Vmax for PNPS than 
HpS. This reflects the enzyme purity, molecular weight and turnover (kcat) for the pH and temperature used 
in the assays. It is likely that much of this difference arises due to the lower purity of HpS which is a crude 
enzyme preparation. In contrast, PaS is purified by affinity chromatography and given the effective post-
translational modification of the active site cysteine to formyl glycine observed on expression in E. coli,[39] 
the kcat for PaS with PNPS measured in this work would be 26 s
–1 at pH 8.8 and 37 °C. This is similar to 
previously determined kcat of 14 s
–1 for PNPS at pH 8 and 25 °C[40] and suggests that the PaS preparation is 
of high purity with the majority of PaS molecules correctly modified with a formyl glycine residue.  
In a urine matrix PaS demonstrated a superior ability to liberate DHEA and EA from their respective sulfate 
conjugates when compared to HpS, although analysis of the latter substrate was complicated by selectivity 
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issues arising from the urine matrix. Of particular importance, the yield of DHEA following hydrolysis with 
PaS was 25% greater than that observed for HpS and 150% greater than acid hydrolysis. In terms of the 
potential for translation to routine sports drug testing analysis, direct hydrolysis of steroid sulfates using 
PaS in urine appears satisfactory, without the need for prior extraction. 
The PaS enzyme was selected as a candidate steroid sulfatase in part because whole cell cultures of P. 
aeruginosa derived from human faecal samples were reported to hydrolyse the sulfate ester of lithocholic 
acid sulfate.[41] As an enteric microbe, this bacterium may rely on sulfatase activity in order to scavenge 
sulfate from bile acid salts.[28] Thus it was our hope that this putative sulfatase activity would be extended 
to other steroid sulfates. Ironically, PaS did not hydrolyse lithocholic acid sulfate in our hands (results not 
shown) and this failure is consistent with the inability to hydrolyse ECS that also contains the 3,5-
configuration of the A-ring. It is possible that the activity observed for P. aeruginosa culture is due to one of 
the other reported sulfatases: AtsK or SdsA1 that are proposed to employ distinct C–O bond cleavage 
pathways.[42][43] 
The selective hydrolysis of sulfate conjugates in the presence of glucuronides presents a significant 
challenge to existing methods. Commercial sulfatase enzyme preparations such as HpS contain 
glucuronidase activity.[3] Chemical methods of hydrolysis such as strong acid[33] generally show poor 
discrimination for the hydrolysis of these phase II conjugates. In contrast the selective cleavage of 
glucuronides can be readily achieved through the agency of E. coli -glucuronidase. The development of 
PaS as a purified enzyme allowed for the selective hydrolysis of steroid sulfate esters in the presence of 
glucuronide conjugates. This was exemplified by the short chemoenzymatic synthesis of ADG 1 (Scheme 2) 
involving the selective PaS-mediated hydrolysis of a sulfate ester protecting group in the presence of a 
steroid glucuronide. Thus PaS provides for the targeted investigations of sulfate esters in complex 
metabolite mixtures that contain glucuronide conjugates. 
 
Conclusions 
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Forty-five years ago, Cawley et al.[35] highlighted the need to develop a general sulfatase preparation for 
clinical analysis of steroid sulfates; a need that has remained essentially unmet to this day.[3] Although 
sulfate ester hydrolysis can be achieved by a range of methods,[3] and the requirement for sulfate 
hydrolysis has been circumvented to some extent by the direct detection of steroid sulfates using LC-MS-
MS methods, mild and selective steroid sulfatase activity would be beneficial for a range of applications 
including routine screening, confirmatory analysis, GC-IRMS and research.  
The recombinantly expressed and purified PaS offers several advantages over HpS and other mollusc-
derived sulfatase preparations in that it has relatively high activity for 3-keto, 17 steroid sulfates and is 
easily purified. The latter trait allows application in selective sulfate ester hydrolysis, exploited in this work 
for the synthesis of ADG 1. The PaS enzyme does not meet the requirements of a general steroid sulfatase 
as it hydrolysed only six of the nine steroid sulfates investigated: no detectable activity was observed for 
the α-configured sulfates ECS, AS and ETS. Even considering this limitation, access to steroid sulfatase 
activity without additional enzyme activities is likely to prove beneficial for range of analytical applications. 
Further, PaS is amenable to improvement because its amino acid sequence and crystal structure are known 
and, in contrast to the mollusc-derived counterparts such as HpS, it can be easily expressed in the 
laboratory. Further engineering will be directed to increasing the substrate scope and improving the 
catalytic efficiency of the PaS enzyme. 
 
Supplementary Information 
Parameters for analyte detection by LC-MS and GC-MS-MS; enzyme concentrations used in assays; SDS-
PAGE gel for the PaS preparation; substrate saturation plots for HpS or PaS with PNPS, ES, EAS and TS; 1H 
and 13C NMR spectra for ADS; 1H NMR conversion spectrum for ADSG; 1H NMR and LRMS for ADG; and GC-
MS-MS chromatograms for DHEA and EA liberated by PaS. 
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Table 1. Substrate range for five sulfatase preparations with 100 µM substrate at 37 °C. The specific activity (mol min–1 [g protein]–1) is represented on a 
logarithmic scale with: 0, no detectable activity; 1, 0.005–0.05; 2, 0.05–0.5; 3, 0.5–5; 4, 5–50; 5, 50–500; 6, 500–5000; and 7, 5000–50000. 
Substrate PNPS ES DHEAS EAS AS ECS TS BS NS ETS 
Sulfate position aromatic aromatic 3 3 3 3 17 17 17 17 
HpS 6 5 3 3 0 2 1 2 1 0 
PaS 7 7 3 3 0 0 2 2 3 0 
HrS 5 3 3 2 0 2 1 0 0 0 
PvS 3 2 1 2 0 0 0 0 0 0 
KpS 2 0 0 0 0 0 0 0 0 0 
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Table 2. Kinetic parameters estimated by non-linear regression for PaS or HpS with four substrates. The values are presented with 95% confidence intervals 
(1.96  standard error of estimate, rounded to one significant figure). Activity was measured in 50 mM ammonium acetate at pH 5.0 for HpS, or in 50 mM 
Tris HCl at pH 8.8 for PaS, and at 37 °C for both. 
Enzyme Kinetic constant PNPS ES EAS TS 
PaS 
Vmax (mol min
–1 [g protein]–1) 25000 ± 1000 17000 ± 2000 0.63 ± 0.05 0.09 ± 0.01 
KM (M) 7 ± 1 14 ± 5 26 ± 8 50 ± 20 
HpS 
Vmax, (mol min
–1 [g protein]–1) 1180 ± 40 270 ± 30 1.53 ± 0.07 0.024 ± 0.007 
KM (M) 17 ± 3 90 ± 30 61 ± 8 60 ± 50 
* PaS exhibited substrate inhibition with ES, KI = 600 ± 400 µM 
  
26 
 
 
Scheme 1. Hydrolysis of testosterone sulfate (TS) to testosterone (T) by PaS. 
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Scheme 2. Chemoenzymatic synthesis of 5-androstane-3,17-diol 17-glucuronide (ADG) 1. 
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Figure 1. Hydrolysis of 5-androstane-3,17-diol 3-sulfate, 17-glucuronide (ADSG) 4 and 5-androstane-3,17-diol 3-sulfate (ADS) 2 by PaS. The reaction 
was run at 37 °C and pH 8.8 with 0.9 g L–1 PaS and ~20 M ADSG. An autosampler was used to periodically inject 1 L samples for analysis by LC-MS to 
measure the relative concentrations of ADSG 4 (), ADS 2 (), and the desired product, 5-androstane-3,17-diol 17-glucuronide (ADG) 1 (o). The 5-
androstane-3,17-diol (AD) product derived from the hydrolysis of ADS 2 could not be detected by this LC-MS method. 
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